



Cost-effectiveness of Lutetium [¹⁷⁷Lu] oxodotreotide *vs* everolimus in gastroenteropancreatic neuroendocrine tumors

Jayne Smith-Palmer, Leeuwenkamp O

Abstract

BACKGROUND

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a relatively rare and heterogenous group of tumors. Currently available treatment options for patients with progressive GEP-NETs include lutetium (¹⁷⁷Lu) oxodotreotide (¹⁷⁷Lu-Dotatate) and everolimus (as well as sunitinib for patients with pancreatic NETs [P-NETs]).

Match Overview

1	Internet 62 words crawled on 13-May-2015 www.ispor.org	1%
2	Crossref 42 words S Roze, J Smith-Palmer, S de Portu, A Delbaere, B de Bro uwer, HW de Valk. "Cost-effectiveness of sensor-augmente	1%
3	Internet 39 words crawled on 22-Feb-2019 bmccancer.biomedcentral.com	1%
4	Internet 38 words crawled on 17-May-2020 worldwidescience.org	1%
5	Internet 35 words crawled on 06-Aug-2017 www.nice.org.uk	1%
6	Internet 34 words crawled on 27-Feb-2020 link.springer.com	1%
7	Crossref 10 words Richard E. Pollock, Bradley H. Curtis, Jayne Smith Palmer	<1%



ALL

IMAGES

VIDEOS

60 Results

Any time ▾

All you need to know about Peptide Receptor Radionuclide ...

<https://ronnyallan.net/2017/05/08/waiting-on-lu-177-prrt> ▾

On 7th Feb 2019, Health Canada approved Lutathera™ (**lutetium (177Lu) oxodotreotide**) for the treatment of unresectable (not removable by surgery) or metastatic, well-differentiated, somatostatin receptor-positive (expressing the somatostatin receptor) **gastroenteropancreatic neuroendocrine tumors** (GEP-NETs) in adults with progressive disease.

everolimus pancreatic | Evidence search | NICE

<https://www.evidence.nhs.uk/search?pa=1&q=everolimus+pancreatic> ▾

Jul 24, 2013 · **Everolimus, lutetium-177 DOTATATE** and sunitinib for advanced, unresectable or metastatic **neuroendocrine** tumours with disease progression: a systematic review and **cost-effectiveness** analysis 14 September 2018 - Publisher: National Institute for Health Research

Pharmacovigilance Risk Assessment Committee (PRAC)

<https://www.ema.europa.eu/en/documents/minutes/...> ▾

Jan 16, 2020 · **Lutetium (177Lu) oxodotreotide** is a β -emitting radionuclide indicated, as Lutathera, for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive **gastroenteropancreatic neuroendocrine** tumours (GEP-NETs) in adults. 19 Centrally authorised product(s) only

sunitinib pancreatic | Evidence search | NICE

<https://www.evidence.nhs.uk/search?q=sunitinib+pancreatic&ps=40> ▾

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic **neuroendocrine** tumours with disease progression: a systematic review and **cost-effectiveness** analysis 14 September 2018 - Publisher: National Institute for Health Research

Neuroendocrine tumor epidemiology - Hauso - 2008 - Cancer ...

<https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.23883>



国内版

国际版

Cost-effectiveness of lutetium (177lu) oxodotreotide vs everolimus in ga



Chat with Bing

Sign in



Microsoft Bing

ALL

IMAGES

VIDEOS

151 Results

Any time ▾

Everolimus, lutetium-177 DOTATATE and sunitinib for ...

<https://www.americanelements.com/research/...> ▾

The risk of bias was low. Although the NETTER-1 (**Neuroendocrine Tumors** Therapy) RCT, of **177Lu-DOTATATE** plus 30 mg of octreotide (Sandostatin, Novartis) compared with 60 mg of octreotide, was excluded from the review, we nonetheless present the results of this trial, as it informs our estimate of the **cost-effectiveness** of **177Lu-DOTATATE**.

All you need to know about Peptide Receptor Radionuclide ...

<https://ronnyallan.net/2017/05/08/waiting-on-lu-177-prrt> ▾

May 08, 2017 · On 7th Feb 2019, Health Canada approved Lutathera™ (**lutetium (177Lu) oxodotreotide**) for the treatment of unresectable (not removable by surgery) or metastatic, well-differentiated, somatostatin receptor-positive (expressing the somatostatin receptor) **gastroenteropancreatic neuroendocrine tumors** (GEP-NETs) in adults with progressive disease.

everolimus pancreatic | Evidence search | NICE

Search Tools

Turn off Hover Translation (关闭取词)



Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

148 Results

Any time ▾

All you need to know about Peptide Receptor Radionuclide ...

<https://ronnyallan.net/2017/05/08/waiting-on-lu-177-prrt> ▾

May 08, 2017 · On 7th Feb 2019, Health Canada approved Lutathera™ (**lutetium (177Lu) oxodotreotide**) for the treatment of unresectable (not removable by surgery) or metastatic, well-differentiated, somatostatin receptor-positive (expressing the somatostatin receptor) **gastroenteropancreatic neuroendocrine tumors** (GEP-NETs) in adults with progressive disease.

Everolimus, lutetium-177 DOTATATE and sunitinib for ...

[https://www.americanelements.com/research/...](https://www.americanelements.com/research/) ▾

The risk of bias was low. Although the NETTER-1 (**Neuroendocrine Tumors** Therapy) RCT, of **177Lu-DOTATATE** plus 30 mg of octreotide (Sandostatin, Novartis) compared with 60 mg of octreotide, was excluded from the review, we nonetheless present the results of this trial, as it informs our estimate of the **cost-effectiveness** of **177Lu-DOTATATE**.

everolimus pancreatic | Evidence search | NICE

<https://www.evidence.nhs.uk/search?pa=1&q=everolimus+pancreatic> ▾

Jul 24, 2013 · **Everolimus, lutetium-177 DOTATATE** and sunitinib for advanced, unresectable or metastatic **neuroendocrine** tumours with disease progression: a systematic review and **cost-effectiveness** analysis 14 September 2018 - Publisher: National Institute for Health Research

Pancreatic Neuroendocrine Tumor Control: Durable Objective ...

<https://www.researchgate.net/publication/278041380...>

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic **neuroendocrine** tumours with disease progression: A systematic review and **cost-effectiveness** ...

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE ...

<https://www.researchgate.net/publication/260841371...>

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic **neuroendocrine** tumours with disease progression: A systematic review and **cost-effectiveness** ...

79517-01-4 | Octreotide Acetate

<https://www.americanelements.com/product/79517-01-4>